Holen Sie sich die Stockscreener-App
0.0195
74.11%
0.0083
Handel nachbörslich:
.02
0.0005
+2.56%
Schlusskurs vom Vortag:
$0.0112
Offen:
$0.0115
24-Stunden-Volumen:
52,841
Relative Volume:
1.80
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+77.27%
1M Leistung:
+116.67%
6M Leistung:
-51.13%
1J Leistung:
-59.63%
1-Tages-Spanne:
$0.0091
$0.0196
1-Wochen-Bereich:
$0.0088
$0.0196
52-Wochen-Spanne:
$0.005
$0.1001
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
Firmenname
Nls Pharmaceutics Ag
Sektor
Branche
Telefon
41 44 512 21 50
Adresse
The Circle 6, Zurich
Vergleichen Sie NLSPW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.0195 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Australia
NLS Pharmaceutics sets terms for $1M private placement - Investing.com
NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa
NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com
NLS Pharmaceutics reveals promising preclinical data - Investing.com
NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan
NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - Seeking Alpha
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - AccessWire
NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com Nigeria
NLSP stock touches 52-week low at $4 amid sharp annual decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire
NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance
NLS Pharmaceutics announces expected compliance with Nasdaq listing rules - TipRanks
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - AccessWire
NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks
NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks
NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com
NLS Pharmaceutics Shareholders Approve Agenda - TipRanks
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com
NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks
Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)
Es liegen keine Finanzdaten für Nls Pharmaceutics Ag (NLSPW) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
1.47%
Kapitalisierung:
|
Volumen (24h):